Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 516

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

Open access
Larkin, James, Minor, David, D'Angelo, Sandra, Neyns, Bart, Smylie, Michael, Miller, Wilson H., Gutzmer, Ralf, Linette, Gerald, Chmielowski, Bartosz, Lao, Christopher D., Lorigan, Paul, Grossmann, Kenneth, Hassel, Jessica C., Sznol, Mario, Daud, Adil, Sosman, Jeffrey, Khushalani, Nikhil, Schadendorf, Dirk, Hoeller, Christoph, Walker, Dana, Kong, George, Horak, Christine, Weber, Jeffrey · 2018 · Journal of Clinical Oncology

Abstract

Purpose: Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma. Patients and Methods: Patients were stratified by programmed death-ligand 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then randomly assigned 2:1 to nivolumab 3 mg/kg intravenously every 2 weeks or investigator’s choice chemotherapy (ICC; dacarbazine 1,000 mg/m 2 every 3 weeks or carboplatin area under the curve 6 plus paclitaxel 175 mg/m 2 every 3 weeks). Patients were treated until they experienced progression or unacceptable toxicity, with follow-up of approximately 2 years. Results: Two hundred seventy-two patients were randomly assigned to nivolumab (99% treated) and 133 to ICC (77% treated). More nivolumab-treated patients had brain metastases (20% v 14%) and increased lactate dehydrogenase levels (52% v 38%) at baseline; 41% of patients treated with ICC versus 11% of patients treated with nivolumab received anti–programmed death 1 agents after randomly assigned therapy. Median OS was 16 months for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 months, respectively (hazard ratio, 1.0; 95.1% CI, 0.78 to 1.436). Overall response rate (27% v 10%) and median duration of response (32 months v 13 months) were notably higher for nivolumab versus ICC. Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (14% v 34%). Conclusion: Nivolumab demonstrated higher, more durable responses but no difference in survival compared with ICC. OS should be interpreted with caution as it was likely impacted by an increased dropout rate before treatment, which led to crossover therapy in the ICC group, and by an increased proportion of patients in the nivolumab group with poor prognostic factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.71.8023

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 516

Metadata

Authors
Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C. D., Lorigan, P., Grossmann, K., Hassel, J. C., Sznol, M., Daud, A., Sosman, J., Khushalani, N., Schadendorf, D., Hoeller, C., Walker, D., Kong, G., Horak, C., & Weber, J.
Venue
Journal of Clinical Oncology
Published
2018-02-01
Volume
36
Issue
4
Pages
383-390
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2726861941
Cited by
516
References
26
FWCI
23.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. https://app.cochat.ai/papers/10.1200/jco.2016.71.8023
The paper
Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C. D., Lorigan, P., Grossmann, K., Hassel, J. C., Sznol, M., Daud, A., Sosman, J., Khushalani, N., Schadendorf, D., Hoeller, C., . . . Weber, J. (2018). Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.71.8023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.